Search Results - "HADJI, P"

Bone health in cancer patients: ESMO Clinical Practice Guidelines by Coleman, R, Body, J J, Aapro, M, Hadji, P, Herrstedt, J

“…There are three distinct areas of cancer management that make bone health in cancer patients of increasing clinical importance. First, bone metastases are…”
Get full text

Bone health in cancer: ESMO Clinical Practice Guidelines by Coleman, R., Hadji, P., Body, J.-J., Santini, D., Chow, E., Terpos, E., Oudard, S., Bruland, Ø., Flamen, P., Kurth, A., Van Poznak, C., Aapro, M., Jordan, K.

“…•The clinical course of advanced cancer for many patients with bone metastases can be transformed through optimum multidisciplinary management.•Bone-targeted…”
Get full text

The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study by McCloskey, E., Rathi, J., Heijmans, S., Blagden, M., Cortet, B., Czerwinski, E., Hadji, P., Payer, J., Palmer, K., Stad, R., O’Kelly, J., Papapoulos, S.

“…Summary This study in 8 countries across Europe found that about 75% of elderly women seen in primary care who were at high risk of osteoporosis-related…”
Get full text

The evolution of selective estrogen receptor modulators in osteoporosis therapy by Hadji, P.

“…Selective estrogen receptor modulators (SERMs), which exhibit estrogen receptor agonist or antagonist activity based on the target tissue, have evolved through…”
Get full text

Bone health in estrogen-free contraception by Hadji, P., Colli, E., Regidor, P.-A.

“…Estrogens and progestogens influence the bone. The major physiological effect of estrogen is the inhibition of bone resorption whereas progestogens exert…”
Get full text

Influence of denosumab on bone mineral density in a severe case of pregnancy-associated osteoporosis by Stumpf, U., Kraus, M., Hadji, P.

“…Pregnancy and lactation-associated osteoporosis (PLO) with predominantly subsequent vertebral fracture is a rare but severe disease with an estimated incidence…”
Get full text

Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting by Kanis, J. A., Cooper, C., Rizzoli, R., Abrahamsen, B., Al-Daghri, N. M., Brandi, M. L., Cannata-Andia, J., Cortet, B., Dimai, H. P., Ferrari, S., Hadji, P., Harvey, N. C., Kraenzlin, M., Kurth, A., McCloskey, E., Minisola, S., Thomas, T., Reginster, J.-Y.

“…Summary Osteoporosis represents a significant and increasing healthcare burden in Europe, but most patients at increased risk of fracture do not receive…”
Get full text

The tamoxifen paradox—influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer by Kyvernitakis, I., Kostev, K., Hadji, P.

“…Summary Our data demonstrate that tamoxifen does not reduce fracture risk. Close surveillance is necessary to prevent bone loss in premenopausal women with…”
Get full text

Subsequent fracture risk of women with pregnancy and lactation-associated osteoporosis after a median of 6 years of follow-up by Kyvernitakis, I., Reuter, T. C., Hellmeyer, L., Hars, O., Hadji, P.

“…Summary Almost a quarter of patients with PAO will sustain a subsequent fracture; patients need to be informed about potential risks before deciding for…”
Get full text

Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF) by Hiligsmann, M., Cornelissen, D., Vrijens, B., Abrahamsen, B., Al-Daghri, N., Biver, E., Brandi, M.L., Bruyère, O., Burlet, N., Cooper, C., Cortet, B., Dennison, E., Diez-Perez, A., Gasparik, A., Grosso, A., Hadji, P., Halbout, P., Kanis, J.A., Kaufman, J.M., Laslop, A., Maggi, S., Rizzoli, R., Thomas, T., Tuzun, S., Vlaskovska, M., Reginster, J.Y.

“…Summary Many patients at increased risk of fractures do not take their medication appropriately, resulting in a substantial decrease in the benefits of drug…”
Get full text

International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates by Diez-Perez, A., Naylor, K. E., Abrahamsen, B., Agnusdei, D., Brandi, M. L., Cooper, C., Dennison, E., Eriksen, E. F., Gold, D. T., Guañabens, N., Hadji, P., Hiligsmann, M., Horne, R., Josse, R., Kanis, J. A., Obermayer-Pietsch, B., Prieto-Alhambra, D., Reginster, J.-Y., Rizzoli, R., Silverman, S., Zillikens, M. C., Eastell, R.

“…Summary Adherence to oral bisphosphonates is low. A screening strategy is proposed based on the response of biochemical markers of bone turnover after 3 months…”
Get full text

Practical guidance for the management of aromatase inhibitor-associated bone loss by Hadji, P., Body, J.-J., Aapro, M.S., Brufsky, A., Coleman, R.E., Guise, T., Lipton, A., Tubiana-Hulin, M.

“…Recent studies indicate that women with breast cancer are at increased risk of fracture compared with their age-matched peers. Current treatment guidelines are…”
Get full text

Pregnancy-associated osteoporosis: a case-control study by Hadji, P., Boekhoff, J., Hahn, M., Hellmeyer, L., Hars, O., Kyvernitakis, I.

“…Summary The etiology and underlying mechanisms of pregnancy-associated osteoporosis (PAO) are still unknown, since no systematic analyses exist. Our results…”
Get full text

Menopausal symptoms and adjuvant therapy-associated adverse events by Hadji, P

“…Third-generation aromatase inhibitors (AIs) are replacing tamoxifen as adjuvant therapy in postmenopausal women with hormone-sensitive breast cancer due to…”
Get full text

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment by Hadji, P., Aapro, M.S., Body, J.J., Bundred, N.J., Brufsky, A., Coleman, R.E., Gnant, M., Guise, T., Lipton, A.

“…Bone mineral density (BMD)-based guidelines for bone-directed therapy in women with early breast cancer (EBC) appear inadequate for averting fractures,…”
Get full text

Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors by Marcucci, G., Beltrami, G., Tamburini, A., Body, J.J., Confavreux, C.B., Hadji, P., Holzer, G., Kendler, D., Napoli, N., Pierroz, D.D., Rizzoli, R., Brandi, M.L.

“…In the past decades, new cancer treatment approaches for children and adolescents have led to a decrease in recurrence rates and an increase in long-term…”
Get full text

Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom by Svedbom, A., Hadji, P., Hernlund, E., Thoren, R., McCloskey, E., Stad, R., Stollenwerk, B.

“…Summary This study estimated the cost-effectiveness of pharmacological fracture prevention as prescribed in the five largest European countries (EU5) using the…”
Get full text

Oral contraceptive use and fracture risk—a retrospective study of 12,970 women in the UK by Dombrowski, S., Jacob, L., Hadji, P., Kostev, K.

“…Summary In the present retrospective case-control study, we compared 6485 women with fractures and 6485 women without fractures from 135 general practitioner…”
Get full text

The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK by Kyvernitakis, I., Kostev, K., Nassour, T., Thomasius, F., Hadji, P.

“…Summary There has been concerning about women receiving depot medroxyprogesterone acetate (DMPA) contraception because of the prolonged hypoestrogenemic state…”
Get full text

Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study by Nestoriuc, Y., von Blanckenburg, P., Schuricht, F., Barsky, A.J., Hadji, P., Albert, U.-S., Rief, W.

“…This study aims to determine the role of patient expectations as potentially modifiable factor of side-effects, quality of life, and adherence to endocrine…”
Get full text